Does Vitamin D Improves Sustained Virologic Response (SVR) in Genotype 2,3 Chronic Hepatitis C Patients?

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-08-31

Study Completion Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Standard therapy for chronic hepatitis C virus (HCV) is (Peg/RBV) combination therapy obtaining sustained virologic response (SVR) in 80% of naïve patients with genotype 2,3. Studies rarely address the issues of improving host factors. The current study examines

1. whether adding vitamin D, a potent immunomodulator, could improve viral response and shorten treatment duration (from 24 weeks to 12 weeks)
2. whether Vitamin D levels predictes negative treatment outcome.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Does 3 Months Therapy With Vitamin D + Peg + Ribavirin Improve Sustained Virologic Response (SVR) in Genotype 2, 3 Chronic Hepatitis C Patients?

NCT01151397

Chronic Hepatitis C

UNKNOWN NA

Efficacy of Vitamin D on Top of Pegylated Interferon and Ribavirin in Patients With Chronic Viral Hepatitis C Null-Responders

NCT01226446

Chronic Hepatitis C

COMPLETED PHASE2

Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients

NCT01439776

Chronic Hepatitis C

COMPLETED PHASE4

Vitamin D as an add-on Therapy With Pegylated Interferon and Ribavirin for Chronic Hepatitis c

NCT01655966

Chronic Hepatitis c

UNKNOWN PHASE3

Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1

NCT01890772

Hepatitis C

WITHDRAWN PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Standard therapy for chronic hepatitis C virus (HCV) is (Peg/RBV) combination therapy obtaining sustained virologic response (SVR) in 80% of naïve patients with genotype 2,3. Studies rarely address the issues of improving host factors. The current study examines whether adding vitamin D, a potent immunomodulator, could improve viral respons.The working hypothesis is that Adding vitamin D to conventional Peg/RBV therapy for naïve, genotype 2,3 patients with chronic HCV infection significantly improves RVR, EVR, and SVR

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Peg+ Vitamin D+ Ribavirine

Group Type ACTIVE_COMPARATOR

Peg+ Vitamin D+ Ribavirine

Intervention Type DRUG

Peg+ Vitamin D+ Ribavirine

Peg+ Ribavirine

Group Type EXPERIMENTAL

Peg+ Ribavirine

Intervention Type DRUG

Peg+ Ribavirine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Peg+ Vitamin D+ Ribavirine

Intervention Type DRUG

Peg+ Ribavirine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 to 65 years of age,
* Chronic genotype 2,3 HCV infection, Traetment Naive
* Negative sero for HBV, HDV and HIV viral infections
* Absolute neutrophil count of \>1500 per cubic millimeter, a platelet count of \>90,000 per cubic millimeter
* Normal hemoglobin level

Exclusion Criteria

* Decompensated liver disease (cirrhosis with CP score \>9)
* Another cause of clinically significant liver disease
* Hepato cellular carcinoma
* Psychiatric Disorder
* Chronic heart failure
* Pregnant women
* Uncontrolled diabetes with retinopathy
* Arythmia
* Active CAD
* Positive sero for HBV, HDV and HIV viral infections or other autoimmune liver disease

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No